UCB company profile

UCB · Euronext Brussels · EUR

€295.70Change from previous close: −0.27%Absolute change: −€0.80

Close · November 16, 2026

Company profile

UCB has 9,000 employees and is headquartered in Brussels, Belgium.

Employing 9,000 people, UCB SA develops medicines for people with neurology and immunology conditions, serving patients worldwide. Epilepsy treatments such as Keppra and Vimpat sit alongside Neupro for Parkinson's disease, while Cimzia and Bimzelx address several inflammatory conditions, including plaque psoriasis and psoriatic arthritis. Evenity, for osteoporosis in postmenopausal women, and Fintepla, for Dravet and Lennox-Gastaut syndromes, add to the range, and the pipeline includes bepranemab for Alzheimer's disease and dapirolizumab pegol for systemic lupus erythematosus. The company also engages in contract manufacturing.

In the fiscal year ended December 2025, revenue reached 7.7 billion euros, up 25.8% from the previous year, and net profit came to 1.6 billion euros. The company was founded in 1925 and its headquarters are in Brussels, Belgium.

Company facts

Industry
Biotechnology
Country
Belgium
Headquarters
Allée de la Recherche, 60, 1070, Brussels
Employees
9,000
Chief executive
Jean-Christophe Tellier
Founded
1925
Fiscal year
January - December
Listing
UCB · Euronext Brussels
Currency
EUR
ISIN
BE0003739530
Website
ucb.com

UCB and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
UCBUCBBelgium$62.48B9,00029.5%26.2
GenmabGMABDenmark$32.21B3,24430.6%47.0
Financière de TubizeTUBBelgium$11.2B3-42,153.6%102.5
ALK-AbellóALK.BDenmark$8.14B2,77326.9%40.7
ABIVAXABVXFrance$7.65B98-6,270.4%—
Bachem HoldingBANBSwitzerland$7.43B2,72521.8%41.9

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare UCB with its competitors